Lindy Biosciences
Lindy Biosciences is a development-stage, privately held biopharmaceutical company that has developed Microglassification™, a proprietary dehydration technology enabling high-concentration subcutaneous protein suspensions, and monetizes it through licensing agreements with pharmaceutical partners such as Novartis.
- Company typePrivate
- Founded2017
- HeadquartersMorrisville, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Lindy Biosciences does
Lindy Biosciences is a development-stage biopharmaceutical company founded in 2017 by Deborah Bitterfield, PhD, and headquartered in Morrisville, NC (Research Triangle Park). It is built around Microglassification™, a proprietary, trade-secret dehydration process that converts biologics into high-concentration protein suspensions suitable for subcutaneous injection. The platform addresses a core formulation bottleneck in modern biologics — delivering sufficient drug mass in small injection volumes — and is positioned as a licensable technology rather than a vertically integrated drug product.
The company monetizes Microglassification™ primarily through licensing and collaboration agreements with pharmaceutical partners, who integrate the process into their own biologic candidates. Its flagship commercial event is the August 2024 licensing/collaboration with Novartis covering Microglassification™-enabled subcutaneous protein therapeutics, with disclosed deal economics of $954M in upfront, development, regulatory, and commercial milestones. To support scale-up beyond internal R&D, Lindy entered a CDMO partnership with Lifecore Biomedical in October 2024 for commercial manufacturing supply, and expanded its Morrisville, NC facility in 2022 to support pipeline growth.
Operationally, Lindy is a small (11–50 employee) private company funded through a series of equity rounds from 2018 through 2022 (cumulative disclosed funding of roughly $6.6M) and led by founder/CEO Deborah Bitterfield, PhD, alongside COO Gary E. Vinson, CFO Omar Flores, and VP Corporate Strategic Partnerships Neil Jones. The business model is classic platform-licensing economics: upfront cash, R&D funding, and milestone- and royalty-linked revenue contingent on partner-driven clinical and commercial progress, which is why the Novartis deal and CDMO relationship are the dominant near-term value drivers and concentration risks.
Lindy Biosciences firmographics
Firmographics- Name
- Lindy Biosciences
- Legal name
- Lindy Biosciences, Inc.
- Website
- https://lindybio.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lindy Biosciences is a development-stage, privately held biopharmaceutical company that has developed Microglassification™, a proprietary dehydration technology enabling high-concentration subcutaneous protein suspensions, and monetizes it through licensing agreements with pharmaceutical partners such as Novartis.
- Ownership category
- akta.pro rank
Lindy Biosciences industry classification
Industry- Product category
- Biotherapeutic Drug Delivery Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)
Keywords
Where Lindy Biosciences is headquartered
LocationHeadquarters
- HQ city
- Morrisville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Lindy Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Technology Licensing and Collaboration: Lindy Biosciences generates revenue through licensing their proprietary Microglassification technology platform to pharmaceutical and biotechnology companies. This includes collaboration agreements with major pharma companies such as the $954 million Novartis partnership for multi-target drug delivery innovation. Revenue comes from upfront payments, milestone payments, and potential royalties on commercialized products.
- Partnership Development: Revenue derived from strategic partnerships with contract development and manufacturing organizations (CDMOs) like Lifecore Biomedical for process development and commercial scale-up support. Services include technology transfer and process development for biotherapeutic products.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Lindy Biosciences product offering
Product offeringCore offering
Lindy Biosciences develops and licenses its proprietary Microglassification™ dehydration technology, which converts aqueous protein solutions into spherical, dense, stable microbeads that can be reconstituted into highly concentrated suspensions (>1 g/mL) suitable for subcutaneous injection. The company commercializes this platform through licensing and collaboration agreements with pharmaceutical partners (e.g., a $954M Novartis multi-target deal), MG Suspension product candidates, and process development / scale-up services delivered via its CDMO partner Lifecore Biomedical.
Product overview
Lindy Biosciences offers a platform-plus-services model centered on its proprietary Microglassification™ technology. The core product is a dehydration technology that produces solid, spherical, amorphous protein microbeads enabling highly concentrated biologics suspensions for subcutaneous injection. The company commercializes this through two main vehicles: (1) MG Suspensions — the formulated drug delivery product that replaces IV infusions with patient self-administered subcutaneous injections; and (2) process development and commercial scale-up services, delivered via a CDMO partnership with Lifecore Biomedical. A $954 million licensing and collaboration agreement with Novartis advances multi-target drug delivery applications using this platform.
Differentiator
Problem solved
Functional benefit
Products and services
- Microglassification™ Platform Technology Proprietary dehydration technology that produces spherical, dense, stable microbeads of therapeutic proteins, enabling highly concentrated suspensions suitable for subcutaneous injection. Licensed to pharmaceutical and biotechnology partners for use in their drug development programs.
- MG Suspensions (Microglassification™ Suspensions) Suspensions of solid protein microbeads that allow subcutaneous delivery of high-dose biologics (monoclonal antibodies and other protein therapeutics), offering an alternative to conventional intravenous infusions in hospital or acute care settings. Targeted at pharmaceutical partners reformulating antibody therapeutics for patient self-administration at home.
- Process Development & Commercial Scale-Up Services (via Lifecore Biomedical CDMO partnership)
Quantifiable outcome
- Over half of all current antibody therapeutics on the market are administered through IV infusion - Microglassification enables conversion to subcutaneous injection
Companies that use Lindy Biosciences
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Lindy Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Lindy Biosciences partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and flagship.
- Lifecore BiomedicalcoreLifecore Biomedical, a fully integrated contract development and manufacturing organization (CDMO), was selected to scale up Lindy Biosciences' innovative microglassification technology for commercial manufacturing. This partnership supports process development and commercial scale-up activities.
- NovartisflagshipLindy Biosciences entered a $954 million licensing and collaboration agreement with Novartis in August 2024 to advance self-administered drug treatments using proprietary microglassification technology for multi-target drug delivery innovation. This represents the company's flagship partnership for developing novel biotherapeutic delivery solutions.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Lindy Biosciences competitors and assessment
Company assessmentOthers
- Croda International: Croda supplies high-purity excipients and delivery-system ingredients used in biologic formulations; it is an adjacent enabler of SC biologic delivery rather than a direct technology competitor to Microglassification™.
- BioLife Solutions: BioLife provides biopreservation tools and formulation/stability services for cell and gene therapies and biologics, adjacent to Lindy's high-concentration biologic formulation niche.
- Lifecore Biomedical: Lifecore is Lindy's CDMO partner for process development and commercial scale-up of Microglassification™; relevant as a comparable injectable-biologics CDMO and as the operational backbone for Lindy's partnered programs.
Broad incumbents
- Antares Pharma: Antares (now part of Halozyme) develops SC and intramuscular auto-injector-based delivery platforms for biologics, addressing the same SC-delivery-for-biologics market where Lindy's Microglassification™ competes.
- Ligand Pharmaceuticals: Ligand licenses multiple platform technologies (e.g., Captisol®, OmniAb®) to pharma partners across small molecules and biologics, and competes broadly with Lindy in the technology-licensing business model applied to drug delivery.
Direct peers
- Alteogen: Alteogen develops hyaluronidase-based and other SC-delivery enabling technologies for biologics and biosimilars, overlapping with Lindy's goal of converting IV antibody therapies to subcutaneous administration.
- Arecor Therapeutics: Arecor specializes in proprietary formulation technologies (Arestat™) that stabilize and concentrate biologics for injection, addressing the same high-concentration protein stability problem Lindy's Microglassification™ targets.
- Halozyme Therapeutics: Halozyme licenses its ENHANZE® recombinant human hyaluronidase platform to major pharma to enable high-concentration, high-volume subcutaneous delivery of biologics—directly analogous to Lindy's Microglassification™ SC-enabling proposition.
- Xeris Biopharma: Xeris develops ready-to-use, room-temperature-stable injectable and SC formulations of biologics and peptides, overlapping with Lindy's focus on improving patient-friendly delivery of therapeutic proteins.
Emerging players
- Ascendia Pharma: Ascendia focuses on poorly soluble and difficult-to-formulate injectable and specialty pharma products, sharing Lindy's emphasis on solving challenging formulation problems for partner pharma programs.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Lindy Biosciences social profiles
Digital presenceLindy Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lindy Biosciences leadership team
Management profileNumber of profiles
Profiles7 records
Lindy Biosciences funding detail
Funding detailFunding overview
Funding rounds7 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lindy Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lindy Biosciences
What does Lindy Biosciences do?
Lindy Biosciences develops and licenses its proprietary Microglassification™ dehydration technology, which converts aqueous protein solutions into spherical, dense, stable microbeads that can be reconstituted into highly concentrated suspensions (>1 g/mL) suitable for subcutaneous injection. The company commercializes this platform through licensing and collaboration agreements with pharmaceutical partners (e.g., a $954M Novartis multi-target deal), MG Suspension product candidates, and process development / scale-up services delivered via its CDMO partner Lifecore Biomedical.
Is Lindy Biosciences a public or private company?
Lindy Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Lindy Biosciences founded?
Lindy Biosciences was founded in 2017. It employs 11 to 50 people.
Where is Lindy Biosciences based?
Lindy Biosciences is headquartered in Morrisville, United States, in the North America region.
How does Lindy Biosciences make money?
Two revenue lines are on record. Technology Licensing and Collaboration is the primary driver. The others are partnership Development.
Who are Lindy Biosciences's main competitors?
Others on record are Croda International, BioLife Solutions and Lifecore Biomedical. Broad incumbents are Antares Pharma and Ligand Pharmaceuticals. Direct peers are Alteogen, Arecor Therapeutics, Halozyme Therapeutics and Xeris Biopharma. Ascendia Pharma is listed as an emerging player.
Does Lindy Biosciences have an API?
No public API is recorded for Lindy Biosciences.
What industry is Lindy Biosciences in?
Lindy Biosciences's product category is Biotherapeutic Drug Delivery Technology. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream). Its NAICS code is 541714 and its SIC code is 8731.